Japan Albumin Market Insight
Published: 27 May 2026 | Report Format: Electronic (PDF)
Japanese market for albumin shows consistent growth with a CAGR of 7.47%, owing to the large requirement for plasma products, the presence of liver and kidney ailments, and increased use of albumin in critical care and biopharmaceutical sectors.
Japan Albumin Market Insights Forecasts to 2035
- The Japan Albumin Market Size Was Estimated at USD 852.4 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.47 % from 2025 to 2035
- The Japan Albumin Market Size is Expected to Reach USD 1752.63 Million by 2035
Notable Insights for Japan Albumin Market
- As per the type of product, human serum albumin is projected to capture around 64-66% of the albumin market in Japan in 2026 as there will be high therapeutic uses of albumin in hypovolemia treatments, liver disorder management, intensive care unit (ICU) treatments, and surgical interventions.
- According to application, therapeutic uses are estimated to occupy nearly 31-33% of the Japan albumin market in 2026 as the number of patients suffering from chronic conditions and critical care visits is likely to increase significantly.
- The advanced healthcare system, increasing aged population, and rising need for plasma-derived drugs are factors driving the growth of albumin treatment and plasma fractionation systems in Japan.
- Increasing capital expenditures in recombinant human serum albumin systems, biopharmaceuticals stabilizing systems, regenerative medicine applications, and advanced plasma separation systems are anticipated to offer lucrative opportunities for market players in Japan.
Download the eBook (ToC)
Why Buy This Report
- Gain comprehensive insights into the Japan albumin market, including market size, growth trends, competitive landscape, and future forecast analysis driving the plasma-derived therapeutics industry.
- Analyze increasing demand for human serum albumin, recombinant albumin products, plasma-derived therapies, and biopharmaceutical stabilization technologies across Japan.
- Identify high-growth investment opportunities through detailed evaluation of plasma fractionation trends, critical care therapy developments, recombinant protein innovations, and strategic healthcare advancements shaping the Japan albumin market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Albumin market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment Market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the Market.
Top Companies in Japan Albumin Market
- Takeda Pharmaceutical Company Limited
- CSL Behring
- Grifols, S.A.
- Japan Blood Products Organization (JBPO)
- KM Biologics Co., Ltd.
- Octapharma AG
- Baxter International Inc.
- Sartorius AG
- Albumedix Ltd.
- China Biologic Products Holdings, Inc.
Recent Developments:
- In March 2026, pharmaceutical companies accelerated investments in recombinant human serum albumin technologies and advanced plasma-derived therapeutics to improve treatment safety, scalability, and supply reliability.
Market Segmentation:
Japan Albumin Market, By Product Type
- Human Serum Albumin
- Recombinant Albumin
- Bovine Serum Albumin
Japan Albumin Market, By Application
- Therapeutics
- Drug Formulation & Stabilization
- Vaccine Production
- Cell Culture Media
- Regenerative Medicine
- Diagnostics
- Others
Japan Albumin Market, By End User
- Hospitals
- Biopharmaceutical Companies
- Research Laboratories
- Blood Banks & Plasma Centers
- Academic Institutes
- Others
Expert Views:
The Japan albumin market is going to grow a lot in the coming years. This is because more people are using plasma therapies. Also there is a lot of money being spent on making proteins in labs. People want treatments when they are very sick. New methods of making human serum albumin will help the market grow. Plasma fractionation and using albumin in medicine are examples. Smarter ways to deliver biopharmaceuticals will also help. The Japan albumin market will also grow because of investments, in biotechnology. This includes making medicines and researching new treatments. This will give companies in Japan many chances to grow.
Author: Sanket and Pranali By Spherical Insights and Consulting